These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 34869480)
1. Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. da Silva KN; Pinheiro PCG; Gobatto ALN; Passos RDH; Paredes BD; França LSA; Nonaka CKV; Barreto-Duarte B; Araújo-Pereira M; Tibúrcio R; Cruz FF; Martins GLS; Andrade BB; de Castro-Faria-Neto HC; Rocco PRM; Souza BSF Front Med (Lausanne); 2021; 8():767291. PubMed ID: 34869480 [No Abstract] [Full Text] [Related]
2. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427 [TBL] [Abstract][Full Text] [Related]
8. pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury. Chen MC; Lai KS; Chien KL; Teng ST; Lin YR; Chao W; Lee MJ; Wei PL; Huang YH; Kuo HP; Weng CM; Chou CL Front Immunol; 2022; 13():871828. PubMed ID: 35585988 [TBL] [Abstract][Full Text] [Related]
9. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P Front Immunol; 2020; 11():1091. PubMed ID: 32574263 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the effects of immunotherapy and mesenchymal stem cells transplantation in the treatment of critically ill coronavirus disease 2019 patients]. Yan Y; Jiang X; Ding D; Huang J Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):139-144. PubMed ID: 33729129 [TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019. Whittaker Brown SA; Iancu-Rubin C; Aboelela A; Abrahams A; Burke E; Drummond T; Grossman F; Itescu S; Lagdameo J; Lin JY; Mark A; Levine JE; Osman K Cytotherapy; 2022 Aug; 24(8):835-840. PubMed ID: 35649958 [TBL] [Abstract][Full Text] [Related]
12. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. Sánchez-Guijo F; García-Arranz M; López-Parra M; Monedero P; Mata-Martínez C; Santos A; Sagredo V; Álvarez-Avello JM; Guerrero JE; Pérez-Calvo C; Sánchez-Hernández MV; Del-Pozo JL; Andreu EJ; Fernández-Santos ME; Soria-Juan B; Hernández-Blasco LM; Andreu E; Sempere JM; Zapata AG; Moraleda JM; Soria B; Fernández-Avilés F; García-Olmo D; Prósper F EClinicalMedicine; 2020 Aug; 25():100454. PubMed ID: 32838232 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Xu X; Jiang W; Chen L; Xu Z; Zhang Q; Zhu M; Ye P; Li H; Yu L; Zhou X; Zhou C; Chen X; Zheng X; Xu K; Cai H; Zheng S; Jiang W; Wu X; Li D; Chen L; Luo Q; Wang Y; Qu J; Li Y; Zheng W; Jiang Y; Tang L; Xiang C; Li L Clin Transl Med; 2021 Feb; 11(2):e297. PubMed ID: 33634996 [TBL] [Abstract][Full Text] [Related]
14. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients? Gardin C; Ferroni L; Chachques JC; Zavan B J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32858940 [TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. Mallis P; Michalopoulos E; Chatzistamatiou T; Stavropoulos-Giokas C World J Stem Cells; 2020 Aug; 12(8):731-751. PubMed ID: 32952855 [TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339 [TBL] [Abstract][Full Text] [Related]
17. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077 [TBL] [Abstract][Full Text] [Related]
18. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. Mattoli S; Schmidt M Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355 [TBL] [Abstract][Full Text] [Related]
19. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge. Feng G; Shi L; Huang T; Ji N; Zheng Y; Lin H; Niu C; Wang Y; Li R; Huang M; Chen X; Shu L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J Stem Cells Dev; 2021 Aug; 30(15):773-781. PubMed ID: 34044609 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report. Kim K; Bae KS; Kim HS; Lee WY Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556900 [No Abstract] [Full Text] [Related] [Next] [New Search]